REFRACTORY LUNG ADENOCARCINOMA

Clinical trials for REFRACTORY LUNG ADENOCARCINOMA explained in plain language.

Never miss a new study

Get alerted when new REFRACTORY LUNG ADENOCARCINOMA trials appear

Sign up with your email to follow new studies for REFRACTORY LUNG ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

New hope for hard-to-treat lung cancer: triple therapy targets resistant tumors

Disease control Recruiting now

This study tests a combination of two targeted drugs (defactinib and avutometinib) plus an immunotherapy (nivolumab) in 50 adults with advanced LKB1-mutant lung adenocarcinoma that no longer responds to standard anti-PD1 treatment. The goal is to see if this triple therapy can sh…

Matched conditions: REFRACTORY LUNG ADENOCARCINOMA

Phase: PHASE2 • Sponsor: Emory University • Aim: Disease control

Last updated Apr 28, 2026 13:02 UTC

REFRACTORY LUNG ADENOCARCINOMA

Get alerted when new REFRACTORY LUNG ADENOCARCINOMA trials appear

New hope for hard-to-treat lung cancer: triple therapy targets resistant tumors